Biologic therapy exposure within 60 days of inflammatory bowel disease-related surgery did not confer a risk for post-operative infectious or surgical site complications, according to research presented at the Crohn’s and Colitis Congress.“We’re all aware that earlier reports from multiple studies suggested that biologics before surgery are associated with increased post-operative morbidity, but it’s been controversial in the last couple of years,” Steven David Holubar, MD, from Cleveland Clinic, said in his presentation. “We aimed to assess potentialRead More